Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularization

Anti-vascular endothelial growth factor therapy for ocular diseases with neovascularization - Anti-VEGF therapy for ocular neovascularization

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011094

Enrollment

510

Registered

2013-07-15

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

choroidal neovascularization diabetic retinopathy retinal vein occulusion neovascular glaucoma retinopathy of prematurity central serous chorioretinopathy

Interventions

Intravitreal injection of Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The presence of active lesions of 1)myopic or secondary choroidal neovascularization 2)diabetic retinopathy 3)retinal vein occulusion 4)neovascular glaucoma 5)retinopathy of prematurity 6)central serous chorioretinopathy

Exclusion criteria

Exclusion criteria: 1)high risk of stroke or myocardial infarction 2)systemic diseases with vessel occulusions 3)ocular infection

Design outcomes

Primary

Measure	Time frame
Change in the visual acuity at 12 months from the initial treatment	—

Secondary

Measure	Time frame
The number of injections required over 12 months of follow-up. The presence or absence of complications.	—

Countries

Japan

Contacts

Public ContactShigeru Honda

Kobe University Graduate school of Medicine Ophthalmology

078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026